Author:
Li Xiaomao,Xiao Lan,Yang Yuebo,Shen Huimin,Zeng Haitao,Wang Zehua
Publisher
Springer Science and Business Media LLC
Subject
Genetics,Biomedical Engineering,Biomaterials,Biochemistry
Reference10 articles.
1. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted anti-tumour therapy. Cell Mol Biol Lett, 2005,10:479–498
2. Xu G, Zhang W, Bertram P et al. Pharmacogenomic profiling of the PI3K/PTEN/AKT/mTOR pathway in common human tumor. Int J Oncol, 2004,24(4):901–908
3. Sahin F, Kannangai R, Adegbola O et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res, 2004,10:8421–8425
4. Ito D, Fujimoto K, Mori T et al. In vivo antitumor effect of the mTOR inhibitor CCI2779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer, 2006,118:2337–2343
5. Altomare D A, You H, Xiao G H et al. Human and mouse mesotheliomas exhibit elevated activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene, 2005,24(40):6080–6089
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献